Abstract
Chemoradiation is the major treatment option in unresectable, locally advanced non-small cell lung cancer. Many clinical trials have evaluated the efficacy of different combinations of chemotherapy and radiotherapy in this heterogeneous patient population. Early clinical trials showed a survival advantage of sequential chemo-RT compared to radiation alone. Subsequent trials demonstrated that concurrent chemo-RT improved survival over sequential chemo-RT. More recent studies have suggested that there is no advantage to adding induction chemotherapy prior to concurrent chemo-RT, or to adding consolidation chemotherapy after concurrent chemo-RT. Various clinical trials have used different chemotherapy regimens, though there is still no consensus about those which are most effective. Additionally, different radiotherapeutic strategies have included hyperfractionation vs. standard fractionation, use of 3-dimensional techniques, and altering total radiation dose. As these methods are being perfected, much attention has turned toward the use of molecularly targeted therapies. This review summarizes recent clinical trials examining the role of chemo-RT in locally advanced non-small cell lung cancer and the movement toward personalized medicine.
Keywords: Locally advanced NSCLC, chemoradiation, molecularly targeted therapy
Reviews on Recent Clinical Trials
Title: Chemoradiotherapy in Locally Advanced, Unresectable Non-Small Cell Lung Cancer
Volume: 4 Issue: 2
Author(s): Lauren R. Mitchell, Jeffrey M. Albert and Bo Lu
Affiliation:
Keywords: Locally advanced NSCLC, chemoradiation, molecularly targeted therapy
Abstract: Chemoradiation is the major treatment option in unresectable, locally advanced non-small cell lung cancer. Many clinical trials have evaluated the efficacy of different combinations of chemotherapy and radiotherapy in this heterogeneous patient population. Early clinical trials showed a survival advantage of sequential chemo-RT compared to radiation alone. Subsequent trials demonstrated that concurrent chemo-RT improved survival over sequential chemo-RT. More recent studies have suggested that there is no advantage to adding induction chemotherapy prior to concurrent chemo-RT, or to adding consolidation chemotherapy after concurrent chemo-RT. Various clinical trials have used different chemotherapy regimens, though there is still no consensus about those which are most effective. Additionally, different radiotherapeutic strategies have included hyperfractionation vs. standard fractionation, use of 3-dimensional techniques, and altering total radiation dose. As these methods are being perfected, much attention has turned toward the use of molecularly targeted therapies. This review summarizes recent clinical trials examining the role of chemo-RT in locally advanced non-small cell lung cancer and the movement toward personalized medicine.
Export Options
About this article
Cite this article as:
Mitchell R. Lauren, Albert M. Jeffrey and Lu Bo, Chemoradiotherapy in Locally Advanced, Unresectable Non-Small Cell Lung Cancer, Reviews on Recent Clinical Trials 2009; 4 (2) . https://dx.doi.org/10.2174/157488709788185969
DOI https://dx.doi.org/10.2174/157488709788185969 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Silybin and Silymarin - New and Emerging Applications in Medicine
Current Medicinal Chemistry Epigenetic Regulation of EMT in Non-Small Cell Lung Cancer
Current Cancer Drug Targets α7 Nicotinic Acetylcholine Receptors: A Therapeutic Target in the Structure Era
Current Drug Targets Targeting the Acute Myeloid Leukemia Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Inhibition of EGFR Signaling by N-cyclohexyl-2-(1-(phenylsulfonyl)piperidin-4-yl) acetamide
Anti-Cancer Agents in Medicinal Chemistry Liquid Biopsy as Surrogate to Tissue in Lung Cancer for Molecular Profiling: A Meta-analysis
Current Respiratory Medicine Reviews Advances in Exploring the Role of Micrornas in Inflammatory Bowel Disease
MicroRNA Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective
Current Pharmaceutical Design Tumor Targeting with RGD Peptide Ligands-Design of New Molecular Conjugates for Imaging and Therapy of Cancers
Anti-Cancer Agents in Medicinal Chemistry Glycation Induced Generation of Amyloid Fibril Structures by Glucose Metabolites
Protein & Peptide Letters Endoglin Silencing has Significant Antitumor Effect on Murine Mammary Adenocarcinoma Mediated by Vascular Targeted Effect
Current Gene Therapy Trafficking of Neuronal Two Pore Domain Potassium Channels
Current Neuropharmacology The Insulin-Like Growth Factor (IGF) Signaling Pathway: Strategies for Successful Therapeutic Tasks in Cancer Treatment
Current Cancer Therapy Reviews Platelet Activity in the Pathophysiology of Inflammatory Bowel Diseases
Current Drug Targets Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy
Current Medicinal Chemistry Pre-feasibility Study for Establishing Radioisotope and Radiopharmaceutical Production Facilities in Developing Countries
Current Radiopharmaceuticals Sleep Disturbances in Lung Cancer Patients
Current Respiratory Medicine Reviews “Endothelial Progenitor Cells” as a Therapeutic Strategy in Cardiovascular Disease
Current Vascular Pharmacology Bypassing Cancer Resistance by Antagonizing “Inhibitor of Apoptosis Proteins” (IAPs)
Current Signal Transduction Therapy PI3K Inhibitors for Cancer Therapy: What has been Achieved So Far?
Current Medicinal Chemistry